<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168301">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02078999</url>
  </required_header>
  <id_info>
    <org_study_id>Ventilator-adquired Pneumonia</org_study_id>
    <secondary_id>VAP2008</secondary_id>
    <nct_id>NCT02078999</nct_id>
  </id_info>
  <brief_title>Biomarkers in Patients Undergoing Mechanical Ventilation</brief_title>
  <acronym>VAP</acronym>
  <official_title>Observational Study in Patients Admitted in the Intensive Care Unit.Tracheal Bacterial Load Surveillance in Patients Undergoing Mechanical Ventilation - Assessment of Biomarkers in the Distinction Between Colonization and Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar Lisboa Ocidental</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Fe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate in a cohort of patients on mechanical ventilation, for non-infectious reasons
      and for documented sepsis of pulmonary as well as non-pulmonary origin, the bacterial load,
      procalcitonine (PCT), C-Reactive Protein (CRP), temperature, White cell count (WCC),
      American College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) consensus
      conference criteria, Sequential Organ Failure Assessment score (SOFA) and simplified
      Clinical Pulmonary Infection Score (CPIS) through the mechanical ventilation period
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypotized that:

        1. In patients on mechanical ventilation for a non-infectious cause of respiratory
           failure, the tracheal bacterial load should be absent or below the cut-off values
           defined for infection, that is to say tracheal colonization.

        2. In patients without the diagnosis of  Ventilator-Adquired Pneumonia (VAP) and not
           taking antibiotics till the weaning process, tracheal bacterial load should remain
           below the predefined cut-off values and the biomarkers (PCT and CRP) should be
           surrogate markers of this clinical course.

        3. In patients developing VAP, an increase in tracheal bacterial load should precede
           diagnosis with an associated rise in the biomarkers levels (PCT and CRP). Finally,
           after institution of antibiotic therapy, adequate therapy should be associated with a
           decrease tracheal bacterial load as well as of the biomarkers (PCT and CRP).

        4. In patients admitted with clinical suspicion of pneumonia, either community-acquired
           (CAP) or hospital-acquired (HAP), with microbiological documentation, after institution
           of antibiotic therapy, adequate therapy should be associated with a decrease tracheal
           bacterial load as well as the biomarkers (PCT and CRP).

        5. In patients admitted with clinical suspicion of a non-pulmonary infection (e.g.
           peritonitis and urosepsis) and on mechanical ventilation for an expected length longer
           than 3 days, either community or hospital-acquired, preferentially with microbiological
           documentation, after institution of antibiotic therapy, adequate therapy should be
           associated with a decrease of biomarkers (PCT and CRP).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Procalcitonine (PCT) levels evolution</measure>
    <time_frame>Up to 21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Procalcitonin (PCT) levels assessed daily up to 21 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein (CRP)</measure>
    <time_frame>Up to 21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the value of serum C-Reactive Protein (CRP) concentrations in the distinction between colonization and pulmonary infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers at day of Ventilator-Adquired Pneumonia (VAP)</measure>
    <time_frame>Up to 21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of  biomarkers namely, copeptin, adrenomedulin, atrial natriuretic peptide, Interleukine 6, Interleukine 1 and hydrogen peroxide</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Control Grup</arm_group_label>
    <description>Daily clinical data collection
Quantitative tracheal aspirates (QTA) every 3 days
Deep freeze serum samples for posterior analysis every day (two aliquots).
In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with pulmonary infection</arm_group_label>
    <description>Daily clinical data collection
Quantitative tracheal aspirates (QTA) every 3 days
Deep freeze serum samples for posterior analysis every day (two aliquots).
In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with extrapulmonary infection</arm_group_label>
    <description>Daily clinical data collection
Quantitative tracheal aspirates (QTA) every 3 days
Deep freeze serum samples for posterior analysis every day (two aliquots).
In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bronchoalveolar lavage,biochemical lab,exhaled air.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted in the ICU
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients admitted in the ICU, with an expected length of mechanical ventilation &gt; 3
             days.

          -  Not receiving antibiotics for &gt;24 hrs before ICU admission- An expected length of
             mechanical ventilation &gt; 3 days

        Exclusion Criteria:

          -  Patients &lt;18 yrs old

          -  Pregnancy and lactation

          -  Fulminant hepatic failure

          -  Pancreatitis

          -  Patients with the diagnosis of disseminated cancer, expected to die or undergo
             withdrawal of treatment within 72 hours after enrolment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>torres antonio, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>hospital vall hebron barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>palomar mercedes, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>hospital clinic i provincial de barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>povoa pedro, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro hospitalario de lisboa occidental</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>antonio artigas, doctor</last_name>
    <phone>93723.3923</phone>
    <email>aartigas@tauli.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>gemma gomà, nurse</last_name>
    <phone>93.723.39.23</phone>
    <email>ggoma@tauli.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>gemma goma, coordinator</last_name>
      <phone>34937233923</phone>
      <email>ggoma@auli.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>August 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Antonio Artigas Raventós</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Mechanical ventilation, procalcitonin, c-reactive protein</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
